CY1117050T1 - CO-OPERATION OF A FACTOR, CONNECTED WITH A TAT Internalisation Peptide, With An Anti-inflammatory Factor - Google Patents

CO-OPERATION OF A FACTOR, CONNECTED WITH A TAT Internalisation Peptide, With An Anti-inflammatory Factor

Info

Publication number
CY1117050T1
CY1117050T1 CY20151101108T CY151101108T CY1117050T1 CY 1117050 T1 CY1117050 T1 CY 1117050T1 CY 20151101108 T CY20151101108 T CY 20151101108T CY 151101108 T CY151101108 T CY 151101108T CY 1117050 T1 CY1117050 T1 CY 1117050T1
Authority
CY
Cyprus
Prior art keywords
factor
tat
inflammatory
histamine release
peptide
Prior art date
Application number
CY20151101108T
Other languages
Greek (el)
Inventor
Michael Tymianski
Jonathan David Garman
Original Assignee
Nono Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08859906.3A external-priority patent/EP2229185B8/en
Application filed by Nono Inc. filed Critical Nono Inc.
Publication of CY1117050T1 publication Critical patent/CY1117050T1/en

Links

Abstract

Η εφεύρεση παρέχει μεθόδους χορήγησης φαρμακολογικών παραγόντων που συνδέονται με ένα πεπτίδιο εσωτερικοποίησης, στις οποίες αναστέλλεται μια φλεγμονώδης ανταπόκριση που προκαλείται από το πεπτίδιο εσωτερικοποίησης με τη συγχορήγηση ενός αντιφλεγμονώδους ή με τη σύνδεση του πεπτιδίου εσωτερικοποίησης με βιοτίνη ή παρόμοιο μόριο. Τέτοιες μέθοδοι προτάσσονται εν μέρει από τα αποτελέσματα που περιγράφονται στα παραδείγματα όπου η χορήγηση ενός φαρμακολογικού παράγονται που συνδέεται με tat σε υψηλές δοσολογίες ακολουθείται στενά από μια φλεγμονώδη ανταπόκριση, που περιλαμβάνει απώλεια των κοκκίων σε μαστοκύτταρα, απελευθέρωση ισταμίνης και το σύνηθες επακόλουθο της απελευθέρωσης ισταμίνης, όπως κοκκίνισμα, έξαψη, πρήξιμο και υπόταση.The invention provides methods of administering pharmacological agents that bind to an internalizing peptide, in which an inflammatory response mediated by the internalizing peptide is inhibited by co-administering an anti-inflammatory or by binding the internalizing peptide to biotin or the like. Such methods are partly supported by the results described in the examples where the administration of a pharmacological derivative associated with tat at high dosages is closely followed by an inflammatory response, including loss of granules in mast cells, histamine release and histamine release, and histamine release. such as redness, flushing, swelling and hypotension.

CY20151101108T 2007-12-05 2015-12-04 CO-OPERATION OF A FACTOR, CONNECTED WITH A TAT Internalisation Peptide, With An Anti-inflammatory Factor CY1117050T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99267807A 2007-12-05 2007-12-05
EP08859906.3A EP2229185B8 (en) 2007-12-05 2008-12-02 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
CY1117050T1 true CY1117050T1 (en) 2017-04-05

Family

ID=58487053

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151101108T CY1117050T1 (en) 2007-12-05 2015-12-04 CO-OPERATION OF A FACTOR, CONNECTED WITH A TAT Internalisation Peptide, With An Anti-inflammatory Factor

Country Status (1)

Country Link
CY (1) CY1117050T1 (en)

Similar Documents

Publication Publication Date Title
CY1122584T1 (en) COMBINATION OF A TAT INTERNALIZING PEPTIDE-BINDING FACTOR WITH AN INHIBITOR OF MAST CELL DEGRADATION
CY1122674T1 (en) ANTI-C5A BINDING MOLECULES WITH HIGH BLOCKING ACTIVITY
CY1122909T1 (en) METHODS OF TREATMENT OF EOSINOPHILIC ESEOPHAGITIS BY ADMINISTRATION OF AN IL-4R INHIBITOR
CY1124071T1 (en) FAPMAKOY ANTI-HER3 ANTIBODY CONJUGATE
CY1123504T1 (en) ANTIDOTES FOR FACTOR HA INHIBITORS AND METHODS OF USING THEM
CY1124844T1 (en) PHARMACEUTICAL ANTIBODY PREPARATION
CY1123626T1 (en) HETEROCYCLIC PROTEIN KINASE INHIBITORS
CY1120426T1 (en) ACE2 polypeptide
CY1123570T1 (en) HEPATITIS B NUCLEAR PROTEIN MODIFIERS
CY1122556T1 (en) SUBSTITUTED N-PHENYLPYRIMIDINE-2-AMINE ANALOGS AS AXL KINASE INHIBITORS
CY1125274T1 (en) METHODS OF TREATING CONDITIONS RELATED TO MASP-2-DEPENDENT COMPLEMENT ACTIVATION
CY1122720T1 (en) T CELL RECEPTORS THAT RECOGNIZE RESTRICTED MAGE-A3 MHC CLASS II
CY1112215T1 (en) PIMOVENDANI TO BE USED TO REDUCE HEART SIZE IN Mammals Suffering From Cardiac Deficiency
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
CY1119219T1 (en) ANTI-CEACAM5 ANTIBODIES AND THEIR USES
CY1122132T1 (en) METHODS OF REDUCING ASTHMA FLASH RATE USING BENRALIZUMAB
CY1121943T1 (en) NUCLEOPHILIC CATALYSTS FOR COUPLING OF ACIDS
MX2018010247A (en) Amanitin conjugates.
BRPI0821004A8 (en) AMINOPYRAZOLE DERIVATIVE COMPOUND, PHARMACEUTICAL COMPOSITION THAT CONTAINS IT AND USE OF IT
CY1119954T1 (en) Oligosaccharides comprising a group of amino acids and their conjugates
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
EA201000211A1 (en) METHOD OF MODELING THE GPR119 RECEPTOR, CONNECTED WITH A G-PROTEIN, AND USED AT THIS CONNECTION
MX2019013690A (en) Cyclodextrin protein drug conjugates.
BR112015027322A8 (en) CONJUGATED ANTI-SENSE COMPOUNDS AND THEIR USE
EA201390940A1 (en) MATERIALS AND METHODS FOR CONJUGATING WATER-SOLUBLE DERIVATIVE FATTY ACID WITH PROTEIN